3 stories mentioning TYO:4547Updated 1d ago
Every FINWIRES story that references TYO:4547, newest first.
Kissei Pharmaceutical (TYO:4547) approved the disposal of 19,794 treasury shares totaling around 78 million yen as part of its restricted stock compensation plan.The shares will be allotted at 3,940 yen each to eight directors and 12 corporate officers, according to a company filing on Tuesday.
Kissei Pharmaceutical (TYO:4547) has submitted a new drug application in Japan seeking manufacturing and marketing approval for olutasidenib, a treatment for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.The drug works by inhibiting the IDH1 metabolic enzyme to restore normal cell differentiation and was originally discovered by Forma Therapeutics, according to at Tokyo bourse filing on Wednesday.Kissei acquired exclusive development and sales rights for Japan, South Korea, and Taiwan from Rigel Pharmaceuticals in September 2024, following olutasidenib's U.S. approval in December 2022.Kissei remains focused on developing new treatments for rare diseases with limited therapeutic options.The submission's impact is already reflected in the company's consolidated financial forecast for the fiscal year ending March 31, 2027.
Kissei Pharmaceutical (TYO:4547) has an average rating of overweight and mean price target of 5,234.29 yen, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
